Abstract

INTRODUCTION

Gallbladder cancer (GBC) is an uncommon and highly fatal carcinoma. It is usually classified with biliary tract cancers in the literature. In this report we have planned to evaluate the clinical characteristics, adjuvant and metastatic treatment options and the survival of GBC patients.

METHODS

A retrospective analysis of GBC patients treated in University of Health Sciences, Dr. A. Y. Ankara Oncology Hospital, Department of Medical Oncology between January 2011 and October 2017 was performed. The files of 58 patients with GBC were screened retrospectively. Treatment regimens, response rates, overall survival (OS) rate and disease-free survival (DFS) of the patients were evaluated.

RESULTS

A total of 58 patients of whom 34 (58.6%) were presented as non-metastatic stage. Thirteen (38.2%) of non-metastatic patients did not receive any adjuvant treatment. Chemoradiotherapy was the most preferred adjuvant treatment option (35.2% of resected patients). Median DFS and OS were 24.8 (95% CI: 1.5- 48.1) and 28 (%95 Cl: 20.6-35.4) months respectively in patients who received adjuvant treatment however both were not reached in patients who did not receive any adjuvant treatment.

DISCUSSION AND CONCLUSION

In resected GBC, it is needed to prospective, randomized controlled trials for adjuvan treatment efficacy and choice of treatment modalities.